Similarly, ALK alterations and their inhibitors do not have the same clinical response in lung tumours as in neuroblastomas.65 Further examples are inhibitors of EGFR, HER2 and HER3, depending on the tumour type and location. The gene discussed is ERBB2; the disease is neoplasm.